Accelerate to Market Genetically Engineered, Off-the-Shelf and Cost Effective NK Cell Immunotherapies for Solid Tumor Indications

Expert Speakers Including:

Anahid Jewett
Professor & Director of Tumor Immunology Laboratory
UCLA School of Dentistry and Medicine

Patrick Soon-Shiong
Founder & CEO
NantWorks

Mark Lowdell
CSO
Innate Bio

Martin Treder
CSO
Affimed AG

Xiaokui Zhang
CSO
Celularity

Robert Igarashi
CSO
Cyto-Sen Therapeutics

Sponsors

Tel: +1 415 735 3289   Mail: info@hansonwade.com   LinkedIn Cell Immunotherapy   @CAR_TCell
Welcome to the Annual Innate Killer Summit

Accelerating NK Cell Understanding to Enhance NK Cell Therapies

Now in its 4th year, the Innate Killer Summit in San Diego is the industry’s most comprehensive forum for advancing the clinical and commercial development of successful NK cell therapies.

The Innate Killer Summit is your opportunity to learn how to optimize your manufacturing and process development strategies to further reduce the cost of off-the-shelf NK cell therapies.

Discuss the most up to date clinical data on genetically engineered NK cells from CARs to bispecific engagers whilst discovering how to improve persistence and durability.

Join over 100 leaders from NantWorks, Affimed, Celularity and ImmuneBio as they share their approaches to overcoming key challenges to accelerate the production of safe, effective and commercially viable cell immunotherapies.

Your Checklist to Advancing NK Cell Therapies

1. **Explore Possible Combinational Therapies to Enhance Immunotherapeutic Response**
   Discover the use of cytokines and targeted antibodies in combination with NK cells to improve their efficacy and understand means to capitalize on the full potential of an immunotherapeutic approach with Martin Treder of Affimed

2. **Assess Clinical Programs to Accelerate your NK Cell Therapies**
   Hear updates on the most advanced clinical programs from Noah Merin at Cedars-Sinai Medical to discover how the application of NK cell therapies are being successfully utilized in the clinic

3. **Achieve Off-the-Shelf Allogeneic Therapies to Improve Treatment Accessibility**
   Hear from James Trager of Nkarta Therapeutics to learn how to adopt the potential of administering “off-the-shelf” NK cell therapies to provide cheaper and more accessible treatments

4. **Review the Tumor Microenvironment to Enhance Clinical Effectiveness**
   Understand the biological cross-talk that occurs with the tumor microenvironment between immunosuppressive factors and immune cells with Mark Lowdell of ImmuneBio to create an effective NK cell-based therapy

5. **Investigate the Regulatory Checkpoints NK Cell Therapies Need to Meet to Ensure Safety and Efficacy**
   Gain an in-depth understanding of the regulatory landscape as NK cell therapies move into clinical investigation to ensure that safety is of the highest standards and successful market approval of your therapy

What Hanson Wade’s attendees have said about our meetings

- Very well organized meeting with top researchers in this field: great overview of a dynamic subject area
  Fate Therapeutics

- Intimate setting where scientists and clinicians can have focused discussions around NK cell biology and clinical translation
  Adheren

- The meeting was excellent. Fantastic presentations on the basic science as well as clinical experience
  Adheren
YOUR EXPERT SPEAKERS

Sonny Hsiao  
CEO  
Acepodia Biotech

Martin Treder  
CSO  
Affimed AG

Robin Parihar  
Assistant Professor of Pediatric Hematology-Oncology  
Baylor College of Medicine

Xiaokui Zhang  
CSO  
Celularity

Robert Hariri  
Chairman & CEO  
Celularity

Noah Merin  
Assistant Professor  
Cedars-Sinai Medical Center

Robert Igarashi  
CSO  
Cyto-Sen Therapeutics

Emily Mace  
Assistant Professor of Pediatrics  
Columbia University

Rizwan Romee  
Director of Haploidentical Donor Transplant Program  
Dana-Farber Cancer Institute

Bob Valamehr  
CDO  
Fate Therapeutics

Amir Horowitz  
Assistant Professor of Oncological Sciences  
Icahn School of Medicine at Mount Sinai

Mark Lowdell  
CSO  
Immune Bio

Lawrence Lamb  
CSO  
Incyus Therapeutics

Evren Alici  
Assistant Professor of Hematology  
Karolinska Institutet

Lotte Wieten  
Department Head of Transplantation Immunology  
Maastricht University

Patrick Soon-Shiong  
Founder & CEO  
NantWorks

James Trager  
Senior Vice President of Research and Development  
Nkarta Therapeutics

Stacey Cranert  
Research Scientist  
Poseida Therapeutics

Anahid Jewett  
Professor & Director of Tumor Immunology Laboratory  
UCLA School of Dentistry and Medicine

Alicja Copik  
Research Assistant Professor & Core Scientist  
University of Central Florida
### Conference Day One | Wednesday 20th March 2019

**9.00 Chair’s Opening Remarks**

**Identifying the Value of NK Cells**

**9.30 The Innate Killing Ability of Natural Killer Cells**
- Emphasizing the need for combinational approaches to combat multiple tumor types
- Addressing the importance of using multiple modes of killing and training to induce an immunogenic response

**10.00 Engineering Models for Potency and Persistence**
- Scalable expansion and transduction of NK cells from a variety of sources to allow maximum flexibility in development of either allogeneic or autologous NK cell products
- Enhancing targeting of NKG2D ligands through the use of conventional chimeras and novel cell engineering approaches
- Maximizing NK potency through combination therapy

**10.30 Morning Refreshments & Speed Networking**

**11.30 NK Cell Memory to Target Advanced Malignancies**
- Update current knowledge about NK cell memory
- Key features of the cytokine induced NK cell memory
- Pre-clinical and early clinical experience with using memory-like NK cells
- Efforts to use memory-like NK cells in combination with novel agents

**12.00 Therapeutic Strategies Based on Innate Immunity and Affimed’s ROCK® platform**
- Outlining Affimed’s versatile modular antibody platform, ROCK® (Redirected Optimized Cell Killing), which enables development of high affinity engagers of innate immune effector cells (NK cells and macrophages), targeting specific receptors on cancer cell
- Effector cell engagement using ROCK®-based bispecific antibodies has shown promising clinical efficacy and safety, both as single agents and in combination with the checkpoint inhibitor pembrolizumab
- ROCK® antibodies with other (immuno-oncology) agents have shown encouraging preclinical results in additional rational combinations with cytokines (IL-2 and IL-15) or with adoptive NK cell transfer

**NK Cell Therapeutic Strategies**

**12.30 Using PM21-NK cells as an Anti-Cancer Therapeutic**
- Use of NK cells for induction of PD-L1 and priming for PD-L1 checkpoint blockade
- Effect of NK cells response on tumor microenvironment
- Use of PM-21-NK cells/anti-PD-L1 checkpoint combinations to improve NK cell function and overall efficacy

**1.00 Lunch & Networking**
2.00 Translation of Pluripotent Cell-Derived Engineered NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy

- Natural killer (NK) cells represent a lineage of immune cells capable of direct cytotoxicity against tumor cells and are a critical source of key inflammatory cytokines
- Pluripotent stem cell technology represents a unique and powerful approach to make cell-based immunotherapies available to a wide range of patients through the generation of a consistent and renewable “off-the-shelf” source of therapeutic cells
- Analogous to biopharmaceutical drug product development, the derived master pluripotent cell line is banked, characterized and repeatedly applied to our stage-specific directed differentiation process to reproducibly and reliably generate NK cells
- Will highlight the therapeutic value of pluripotent-derived NK cells including augmented anti-tumor capacity, manufacturing reliability and product safety

2.30 Refinement of NK Cell Immunotherapy: Strategies to Unleash the Killer in a Suppressive Tumor Microenvironment

- Preclinical data supporting the use of alloreactive NK cells as immunotherapy for breast cancer
- Comprehensive analysis of the functional relevance of HLA and inhibitory receptors for NK cell alloreactivity in breast cancer
- Development of combinational strategies to maximize the anti-tumor potential of NK cells in a suppressive tumor microenvironment in haematological- and solid tumors

3.00 Utilizing Ex Vivo Expanded Natural Killer Cells for Both Allogeneic and Autologous Uses

- Discussing monoclonal therapies and NK cell activity
- Strategies to combine adoptive NK cell therapies with monoclonal antibody therapies
- Examining bottlenecks and strategies to overcome them in NK cell based immunotherapy clinical trials

4.00 Antibody-Cell Conjugation to NK Cells Without Genetic Engineering

- Novel technology ACC (Antibody-Cell Conjugation) to chemically conjugate antibodies to NK cells without genetic engineering
- Signaling pathways activated by novel ACC-NK
- Testing ACC-NK’s performance in serum and in suppressive tumor microenvironment
- Testing ACC-NK using in vivo xenograft models of liquid tumors and solid tumors.

4.30 Panel Discussion: The Future Potential of NK Cells in Combination Therapies

- Identify the optimal sequence of treatment for successful combination therapy and detail their development in animal studies
- Explore the use of targeted antibodies and cytokines to work alongside NK cells to improve their role in persistence and anti-tumor effects
- Understand the cross-talk between NK cells and T cells, analyzing how an inflammatory microenvironment can stimulate the rest of adaptive immunity to work in combination to increase efficacy
- Understand ways to exploit the full potential of an immunotherapeutic approach, defining a rational combination approach to maximize efficacies

5.00 Chair’s Closing Remarks

5.45 End of Day One
### Tumor Microenvironment and NK Cell Therapy

#### 9.00 Chair’s Opening Remarks

**Anahid Jewett**  
Professor & Director of Tumor Immunology Laboratory  
UCLA School of Dentistry & Medicine

#### 9.30 Investigating the Consequences of Co-Incubation of Freshly Isolated, Resting NK Cells with K562, CTV-1, Daudi and RPMI-8226 Tumor Cell Lines on the Phenotype, Cytokine Profile and Transcriptome of the NK Cells

- Examining specific tumor-induced NK cell signatures  
- Highlighting the key signaling molecules exclusively affected by tumor-priming  
- Understanding tumor-specific NK cell responses in the tumor microenvironment

**Mark Lowdell**  
CSO  
Immune Bio

#### 10.00 Distinguishing Undifferentiated Tumors from Differentiated Tumors

- NK cells are the effectors of selection and differentiation of Cancer Stem Cells/undifferentiated tumors in pancreatic, melanoma, glioblastoma, lung, breast and oral tumors  
- We have identified and characterized combination of surface receptor markers which distinguish stem-like/undifferentiated tumors from differentiated tumors and have used to identify the degree and effectiveness of patient NK cells in differentiation of tumors  
- Membrane bound and secreted forms of IFN-γ and TNF-α from NK cells are key cytokines in limiting tumor growth through differentiation of the tumors  
- NK inactivation occurs at the pre-neoplastic stage of tumorigenesis and becomes more severe at the neoplastic stage due to both the genetic and environmental factors  
- Factors contributing to the dysfunctional state of cancer patients’ NK cells are lack of expansion of NK cells, severe decrease in NK cell cytotoxicity, decreased secretion of IFN-γ by the NK cell and lack of ability of secreted IFN-γ to differentiate tumors

**Anahid Jewett**  
Professor & Director of Tumor Immunology Laboratory  
UCLA School of Dentistry & Medicine

#### 10.30 Morning Refreshments & Networking

**Robin Parihar**  
Assistant Professor of Pediatric Hematology-Oncology  
Baylor College of Medicine

#### 11.00 NK Cells and the Solid Tumor microenvironment: Lessons Learned and Translational Potential

- Understand the role of the tumor immune microenvironment in patients receiving adoptive cellular therapy  
- Discuss a novel xenograft model of the TME for understanding mechanisms that limit immune therapies in solid tumors  
- Characterize the differing roles of MDSCs, inhibitory macrophages, and Tregs of the TME in affecting adoptive cellular therapies

**Amir Horowitz**  
Assistant Professor of Oncological Sciences  
Icahn School of Medicine at Mount Sinai

#### 11.30 Harnessing NK Cells to Improve T-cell Targeted Immunotherapies for Solid Tumor and Hematologic Malignancies

- Exploring the under-appreciated layer of complexity around HLA-E-mediated inhibition and regulation of NK cell functions in the tumor microenvironment  
- Examining the effects of HLA-E expression and presence or absence of KIR ligands on tumor cells on prognosis and survival of cancer patients across numerous settings of hematologic and solid tumor malignancies  
- Tumor response to immune checkpoint blockade therapies

**Amir Horowitz**  
Assistant Professor of Oncological Sciences  
Icahn School of Medicine at Mount Sinai
12.00 **Panel Discussion: Identifying Strategies to Improve Efficacy in Solid Tumor Trials**
- Strategies to allow NK cells to cross barriers into solid tumors and overcome strong immunosuppressive environments
- Do immune-regulatory cells impact NK and T cells in the same way?
- Discuss the potential of downregulating TGF-beta to allow for greater NK activity

1.00 **Lunch & Networking**

**Clinical Trial Case Studies**
Hear updates on the most advanced clinical programs to discover how the application of NK cell therapies are being successfully utilized in the clinic.

2.00 **An Allogeneic, Off-The-Shelf NK Cell Product Derived from Placental Hematopoietic**
- Clinical studies suggest that adoptive transfer of allogeneic natural killer (NK) cells represent a promising treatment for patients with hematological malignancies and solid tumors
- Celularity is developing an allogeneic, off-the-shelf NK cell product that is derived from placental hematopoietic stem cells and exhibits substantial cytolytic activity against various cancer cell lines, primary AML and primary MM cells
- Clinical and translational development of Celularity NK cell product will be discussed

2.30 **Pre-emptive Donor-Derived Natural Killer Infusion for Patients with High-risk Multiple Myeloma, Lymphoma, or CLL**
- Attempting to add-back mature donor NK and NK/T cells after PTCy to hasten NK immune recovery
- Outlining the two separate pheresis sessions donors undergo
- Methods to evaluate abundance of NK receptor ligands, NK phenotype, KIR expression and inhibitory/activating receptors

3.00 **NK Cell Stimulation Using Membrane Bound IL-21**
- Addressing the needed for an effective and robust methodology for efficient production of large doses of NK cells with high anti-tumor potency
- NK cell stimulation for production of high dosages and repeat dosages of highly potent NK cells
- Advancing clinical development of NK cell therapeutics for treatment of AML in the near future

3.30 **Afternoon Refreshments**

**Identifying Key Manufacturing Considerations for Efficient Large Scale Treatments**

3.40 **Addressing Contact-Dependent Factors that Promote NK Cell Development**
- Human natural killer (NK) cell development is a poorly understood process, particularly the nature of cell-cell contacts that shape NK cell functional maturation
- Understanding the contact-dependent factors that promote NK cell development will better inform the design of rational NK cell-based immunotherapy
- Here I will describe recent findings that have advanced our understanding of the generation of NK cell heterogeneity and functional phenotypes using novel in vitro and ex vivo systems

4.30 **Chair’s Closing Remarks**

4.45 **Close of Summit**
To challenge the ineffective inflammatory responses within the tumor microenvironment due to inactivation of NK cells which support tumor evasion, we must identify the factors which contribute to the dysfunctional state of NK cells in patients and understand the intricate net of interactions occurring between the tumor cells and immune cells within the tumor microenvironment. Attend this workshop to learn how the tumor escapes NK cell's ability to contain them, and establishes itself with the aid of other tumor supportive cells, which are also controlled by the NK cells, within the tumor microenvironment.

Attendees will learn:
- The many challenges posed by solid and liquid tumors and their varying tumor microenvironments
- Techniques to create an effective NK cell-based therapy that are capable of overcoming the immunosuppressive environments of tumors, and understand their mechanisms of actions

Dr. Jewett is Professor and Director of tumor immunology laboratory in the Division of Oral Biology and Medicine, and Weintraub Center for reconstructive biotechnology at the UCLA School of Medicine and Dentistry. She has membership in Johnsson Comprehensive Cancer Center (JCCC) and is a member of UCLA Tumor Immunology subgroup. She is well-known nationally and internationally for her contribution to the field of NK biology, tumor immunology and cancer immunotherapy. She has received a large number of honors and awards and holds memberships in many professional organizations and societies.

Dr. Lawrence Lamb is a Clinical Laboratory Immunologist and Professor of Medicine at the University of Alabama at Birmingham, specializing in transplantation immunology. Dr. Lamb directs the UAB Cell Therapy Laboratory in the Section of Bone Marrow Transplant and Cellular Therapy. While a Transplantation Medicine postdoctoral fellow at the University of South Carolina, Dr. Lamb was the first to describe homeostatic reconstitution of γδ T cells in patients who receive αβ T cell depleted bone marrow grafts as well as an association between γδ T cell recovery and disease-free survival in allogeneic bone marrow. He currently directs research programs for evaluation and translation of γδ T cell-based therapies for Glioblastoma Multiforme and Leukemia has received funding by the NINDS, NCI, Elsa Pardee Foundation, Leukemia and Lymphoma Society, the Brendan Franco Foundation, and the Southeastern Brain Tumor Foundation. He also held the National Brain Tumor Society’s Samuel Gerson Leadership Chair for Glioblastoma Research for 2008-2010. Dr. Lamb serves on several national and international committees related to cell and gene therapy and currently chairs the Scientific Advisory Board for Incysus Therapeutics, Inc.
As effective NK cell therapies for cancer therapy begin to fulfill their potential, a key challenge has been the availability of an effective methodology for the efficient production of large doses of NK cells with high anti-tumour potency. Attend this workshop to understand the logic and rationale behind CytoSen’s approach for high NK cell doses and the therapeutic application of them.

Attendees will learn:
• The reasons for needing high doses of NK cells
• The potential of NK cell therapies which have efficient production of large doses of NK cells

Robert Igarashi, Ph.D. is the president and co-founder of CytoSen Therapeutics. Dr. Igarashi has a diverse background in life sciences and has played an instrumental role in the development of the particle based natural killer (NK) cell stimulating technology. He has brought his biochemical and physico-chemical expertise to combine with immunology for developing and refining the nanoparticle based method for NK cell stimulation that could be used for ex vivo expansion as well as in vivo stimulation of therapeutic NK cells. He has been crucial in understanding the biochemical aspects of the plasma membrane particles interacting with NK cells and how they can be further innovated to add novel therapeutic dimensions for adoptive NK cell therapy.

Workshop D

Logic and Rationale Behind the High Doses of High Potency NK Cells and their Therapeutic Application

19th March 1:00pm - 4:00pm

As effective NK cell therapies for cancer therapy begin to fulfill their potential, a key challenge has been the availability of an effective methodology for the efficient production of large doses of NK cells with high anti-tumour potency. Attend this workshop to understand the logic and rationale behind CytoSen’s approach for high NK cell doses and the therapeutic application of them.

Attendees will learn:
• The reasons for needing high doses of NK cells
• The potential of NK cell therapies which have efficient production of large doses of NK cells

Robert Igarashi, Ph.D. is the president and co-founder of CytoSen Therapeutics. Dr. Igarashi has a diverse background in life sciences and has played an instrumental role in the development of the particle based natural killer (NK) cell stimulating technology. He has brought his biochemical and physico-chemical expertise to combine with immunology for developing and refining the nanoparticle based method for NK cell stimulation that could be used for ex vivo expansion as well as in vivo stimulation of therapeutic NK cells. He has been crucial in understanding the biochemical aspects of the plasma membrane particles interacting with NK cells and how they can be further innovated to add novel therapeutic dimensions for adoptive NK cell therapy.

It was tremendously exciting to share our collective advances and learn from each other as we move forward in developing the next generation of therapies.

MD Anderson Cancer Center

Tel: +1 415 735 3289     Mail: info@hansonwade.com
www.innate-killer.com    Cell Immunotherapy    @CAR_TCell
Exhibit: Exhibitor
Miltenyi Biotec’s mission is to improve scientific understanding and medical progress. By developing innovative products that address the processes that are necessary for the study of immuno-oncology we help researchers advance science in these key areas as well as help clinicians to make the concept of cellular therapy a reality.

www.miltenyibiotech.com

Exhibit: Exhibitor
Since our start in 2006, research and development efforts at Akron Biotech have led to discoveries that have fuelled the development of some of the most innovative products to support cell and gene therapy research, clinical development and commercialization. Now, Akron operates from a 14,000 sf facility in Boca Raton as a leader in innovation and cGMP manufacturing.

www.akronbiotech.com

Innovation: Innovation Partner
Irvine Scientific, a member of JXTG Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cyto genetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support.

www.irvinesci.com

Innovation: Innovation Partner
CTL specializes in cellular immune monitoring, and was the first entity to validate ELISPOT assays for clinical trials, also patenting the first automated ELISPOT analyzer. CTL’s NK-TVA platform is an extension of our immune monitoring efforts, and provides an image cytometry platform for measuring NK cell cytolytic activity, as well as ADCC, and CD8 T cell cytotoxicity. NK-TVA is a high-throughput, non-radioactive alternative to traditional 51Cr-release assays, using direct, fluorescence-based cell imaging.

www.immunospot.com

Innovation: Innovation Partner
IsoPlexis, develops novel solutions that are accelerating the revolution in immune and cell-based treatments of cancer. The Isolight, a next-generation analytics platform, profiles responses at the single-cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex response to cancer immunotherapies.

www.isoplexis.com

Contact: GET INVOLVED
Luke O’Neill
Partnerships Director
Tel: +44203 8541 823
Email: sponsor@hansonwade.com

100+
ATTENDEES
50+
COMPANIES
40%+
DIRECTOR
LEVEL & ABOVE
50%+
PHARMACEUTICAL
& BIOTECH DRUG
DEVELOPERS

Tel: + 1 415 735 3289     Mail: info@hansonwade.com
www.innate-killer.com
**SECURE YOUR PLACE**

<table>
<thead>
<tr>
<th>Vendor Pricing</th>
<th>Register &amp; Pay before Friday, December 14 (Save $500)</th>
<th>Standard Prices</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD Conference + 2 Workshops</td>
<td>$3,997</td>
<td>$4,497</td>
</tr>
<tr>
<td>SILVER Conference + 1 Workshop</td>
<td>$3,398</td>
<td>$3,898</td>
</tr>
<tr>
<td>BRONZE Conference Only</td>
<td>$2,799</td>
<td>$3,299</td>
</tr>
<tr>
<td>Workshop Only</td>
<td>$699</td>
<td></td>
</tr>
</tbody>
</table>

**Drug Developer Pricing**

<table>
<thead>
<tr>
<th>Register &amp; Pay before Friday, December 14 (Save $700)</th>
<th>Standard Prices</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD Conference + 2 Workshops</td>
<td>$3,197</td>
</tr>
<tr>
<td>SILVER Conference + 1 Workshop</td>
<td>$2,698</td>
</tr>
<tr>
<td>BRONZE Conference Only</td>
<td>$2,199</td>
</tr>
<tr>
<td>Workshop Only</td>
<td>$599</td>
</tr>
</tbody>
</table>

**Academic Pricing**

<table>
<thead>
<tr>
<th>Register &amp; Pay before Friday, December 14 (Save $500)</th>
<th>Standard Prices</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD Conference + 2 Workshops</td>
<td>$1,997</td>
</tr>
<tr>
<td>SILVER Conference + 1 Workshop</td>
<td>$1,598</td>
</tr>
<tr>
<td>BRONZE Conference Only</td>
<td>$1,199</td>
</tr>
<tr>
<td>Workshop Only</td>
<td>$499</td>
</tr>
</tbody>
</table>

**TERMS AND CONDITIONS**

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 15 days before the conference attendees will receive a full refund. Cancellation 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

**Team Discounts**

- 10% discount – 5 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Contact: register@hansonwade.com

**VENUE**

Hilton San Diego Gaslamp Quarter
401 K Street, San Diego, California. 92101, USA

For further information or assistance, please visit

**Participant Notes**

- **Network** with the experts and leaders of the Innate Killer Community and take this opportunity to make collaborative partnerships for future clinical prospects.
- **Hear** the novel clinical data from NK trials and apply the lessons learnt to future NK pipelines to ensure future efficacy.
- **Learn** from the leaders in the space and join the communal discussion finding solutions to limiting manufacture and regulatory issues.

**Ready to Register?**

**3 Easy Ways to Book**

- Tel: + 1 415 735 3289
- Email: register@hansonwade.com

**4th Annual Innate Killer Summit**
19–21 March 2019 | San Diego